Kymera Therapeutics, Inc.

KYMRBiotech

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 21

By Therapeutic Area

top 2

Immunology

150%

Respiratory

150%

R&D Momentum

40/100

Pipeline Velocity

22/100

Trial Completion Rate

100/100

Pipeline Concentration

50/100

Pipeline Freshness

95/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Nov 3, 2026

Completed

A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants

Oct 31, 2026

Recruiting

A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of Different Oral Formulations of KT-621 in Healthy Adult Participants

Earlier

Oct 8, 2026TrialA Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Oct 7, 2026TrialA Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Oct 7, 2026TrialA Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma

Apr 17, 2025TrialSafety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)

Oct 22, 2024TrialFirst-in-human Study of Orally Administered KT-621 in Healthy Adult Participants

May 15, 2023TrialSafety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors

3 more events

Jun 13, 2022TrialSafety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

May 19, 2022TrialSafety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Feb 23, 2021TrialA Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Details